JP2016539629A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539629A5 JP2016539629A5 JP2016524423A JP2016524423A JP2016539629A5 JP 2016539629 A5 JP2016539629 A5 JP 2016539629A5 JP 2016524423 A JP2016524423 A JP 2016524423A JP 2016524423 A JP2016524423 A JP 2016524423A JP 2016539629 A5 JP2016539629 A5 JP 2016539629A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- ltr
- vector according
- optional
- retroviral vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001177 retroviral effect Effects 0.000 claims 16
- 238000004806 packaging method and process Methods 0.000 claims 12
- 210000002845 virion Anatomy 0.000 claims 8
- 238000000034 method Methods 0.000 claims 4
- 108700019146 Transgenes Proteins 0.000 claims 3
- 238000001415 gene therapy Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000010839 reverse transcription Methods 0.000 claims 2
- 238000013518 transcription Methods 0.000 claims 2
- 230000035897 transcription Effects 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108091027981 Response element Proteins 0.000 claims 1
- 108700009124 Transcription Initiation Site Proteins 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000008488 polyadenylation Effects 0.000 claims 1
- 230000001124 posttranscriptional effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1318347.0 | 2013-10-16 | ||
| GBGB1318347.0A GB201318347D0 (en) | 2013-10-16 | 2013-10-16 | Retroviral vectors |
| PCT/GB2014/053102 WO2015056014A1 (en) | 2013-10-16 | 2014-10-16 | Retroviral vectors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539629A JP2016539629A (ja) | 2016-12-22 |
| JP2016539629A5 true JP2016539629A5 (enExample) | 2017-11-24 |
| JP6525986B2 JP6525986B2 (ja) | 2019-06-05 |
Family
ID=49680159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016524423A Active JP6525986B2 (ja) | 2013-10-16 | 2014-10-16 | レトロウイルスベクター |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10184136B2 (enExample) |
| EP (1) | EP3058076B1 (enExample) |
| JP (1) | JP6525986B2 (enExample) |
| CN (1) | CN105705645B (enExample) |
| ES (1) | ES2759049T3 (enExample) |
| GB (1) | GB201318347D0 (enExample) |
| WO (1) | WO2015056014A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| SG11201809096VA (en) | 2016-04-20 | 2018-11-29 | Centro De Investigaciones Energeticas Medioambientales Y Tecnologicas | Compositions and methods for enhanced gene expression of pklr |
| US20190203225A1 (en) * | 2016-09-08 | 2019-07-04 | Centro de Investigaciones Energéticas, Medioambientales y Technológicas O.A, M.P. | Gene therapy for patients with fanconi anemia |
| JP7290288B2 (ja) * | 2017-08-22 | 2023-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 免疫不全及び自己免疫疾患を治療するための、造血幹細胞でｆｏｘｐ３を発現するレンチウイルスベクター |
| CN111163810B (zh) | 2017-10-16 | 2024-09-10 | 能源环境和技术研究中心O.A.,M.P. | 用于递送pklr以治疗丙酮酸激酶缺乏症的慢病毒载体 |
| MX2020011386A (es) | 2018-04-27 | 2021-01-29 | Spacecraft Seven Llc | Terapia genica para la degeneracion del snc. |
| CN108676815A (zh) * | 2018-05-31 | 2018-10-19 | 深圳市免疫基因治疗研究院 | 一种b型血友病慢病毒载体、慢病毒及其制备方法和应用 |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| US20210386788A1 (en) | 2018-10-24 | 2021-12-16 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| WO2020185632A1 (en) | 2019-03-08 | 2020-09-17 | Obsidian Therapeutics, Inc. | Human carbonic anhydrase 2 compositions and methods for tunable regulation |
| US20240124889A1 (en) | 2019-05-07 | 2024-04-18 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| EP3983537A1 (en) | 2019-06-12 | 2022-04-20 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| US20220259284A1 (en) | 2019-06-12 | 2022-08-18 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| US20230092895A1 (en) | 2019-08-30 | 2023-03-23 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| WO2022032226A1 (en) | 2020-08-07 | 2022-02-10 | Spacecraft Seven, Llc | Plakophilin-2 (pkp2) gene therapy using aav vector |
| GB202019084D0 (en) * | 2020-12-03 | 2021-01-20 | Ucl Business Ltd | Retroviral vectors |
| CN117043337A (zh) * | 2021-01-25 | 2023-11-10 | 普利维尔治疗公司 | 基于aav的基因表达的调节 |
| AU2022301302A1 (en) | 2021-07-01 | 2024-01-25 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| EP4473097A1 (en) | 2022-02-02 | 2024-12-11 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| CN114931652B (zh) * | 2022-06-23 | 2024-01-26 | 中国人民解放军陆军军医大学第一附属医院 | 一种Hmga2基因在修复受损视网膜中的应用 |
| CA3259982A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics, Inc. | COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| GB202306491D0 (en) | 2023-05-03 | 2023-06-14 | Ucl Business Ltd | Retroviral vectors |
| CN120738286A (zh) * | 2025-07-03 | 2025-10-03 | 北京石油化工学院 | 过表达Bag6的CHO细胞株在制备提升外源重组蛋白表达量中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2707091B1 (fr) * | 1993-06-30 | 1997-04-04 | Cohen Haguenauer Odile | Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes. |
| US5714353A (en) * | 1994-05-24 | 1998-02-03 | Research Corporation Technologies, Inc. | Safe vectors for gene therapy |
| FR2751345B1 (fr) | 1996-07-16 | 1998-09-18 | Univ Paris Curie | Lignees d'encapsidation hautement productrices |
| US20050266544A1 (en) | 1999-04-30 | 2005-12-01 | Human Gene Therapy Research Institute | Methods and compositions for increasing viral vector production in packaging cell lines |
| US8158413B2 (en) * | 2005-10-17 | 2012-04-17 | Institut Pasteur | Lentiviral vector-based vaccine |
| US20070048285A1 (en) * | 2005-08-24 | 2007-03-01 | Christopher Baum | Self-inactivating retroviral vector |
| CN102443604B (zh) * | 2011-11-25 | 2014-12-31 | 上海市儿童医院 | 一种安全性慢病毒载体及其应用 |
-
2013
- 2013-10-16 GB GBGB1318347.0A patent/GB201318347D0/en not_active Ceased
-
2014
- 2014-10-16 CN CN201480057140.0A patent/CN105705645B/zh active Active
- 2014-10-16 WO PCT/GB2014/053102 patent/WO2015056014A1/en not_active Ceased
- 2014-10-16 ES ES14787036T patent/ES2759049T3/es active Active
- 2014-10-16 US US15/029,898 patent/US10184136B2/en active Active
- 2014-10-16 JP JP2016524423A patent/JP6525986B2/ja active Active
- 2014-10-16 EP EP14787036.4A patent/EP3058076B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539629A5 (enExample) | ||
| JP2011505835A5 (enExample) | ||
| FI3546585T3 (fi) | Muokatun intronin käsittäviä nukleiinihappoja käytettäviksi hyperbilirubinemian hoidossa | |
| JP2016521554A5 (enExample) | ||
| RU2018122636A (ru) | Стабильные клеточные линии для продуцирования ретровирусов | |
| JP2016528919A5 (enExample) | ||
| MX390848B (es) | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos. | |
| JP2017505117A5 (enExample) | ||
| JP2016528918A5 (enExample) | ||
| JP2016528916A5 (enExample) | ||
| JP2017532302A5 (enExample) | ||
| JP2018520997A5 (enExample) | ||
| EA201690545A1 (ru) | Онколитические аденовирусы, несущие гетерологичные гены | |
| JP2018534937A5 (enExample) | ||
| EP4600366A3 (en) | Cas 9 retroviral integrase systems for targeted incorporation of a dna sequence into a genome of a cell | |
| JP2017501695A5 (enExample) | ||
| EA201692361A1 (ru) | Лентивирусные векторы | |
| EP4659816A3 (en) | MODIFIED CAPSID PROTEINS FOR IMPROVED PARVOVIRUS VECTOR DELIVERY | |
| JP2017538401A5 (enExample) | ||
| JP2011004755A5 (enExample) | ||
| JP2016501531A5 (enExample) | ||
| JP2008056679A5 (enExample) | ||
| JP2008545406A5 (enExample) | ||
| WO2015158749A3 (de) | Viraler vektor für den zielgerichteten gentransfer in gehirn und rückenmark | |
| JP2018522595A5 (enExample) |